Main Navigation
Mercia
Ventures
Debt
Private equity
Contact us
About us
Investment strategies
Investor area
PLC
EIS
VCT
Contact us
Audience
|
Change
Ventures
Debt
Private equity
Contact us
About us
About us
Our history
Our vision and values
University partnerships
Team
Careers
Portfolio
Sustainability
Strategies
Our investment strategy
Our funds
Strategic assets
Property development finance
EIS & VCT
For shareholders
Share price
Board of directors
Financial reports & presentations
Regulatory news
Corporate governance
AIM Rule 26
Organisational structure
Annual Report
VCT
Northern Venture Trust
Northern 2 VCT
Northern 3 VCT
Insights & Research
Hub
Ventures
Debt
Private equity
Contact us
About us
Investment strategies
Investor area
PLC
EIS
VCT
Contact us
About us
About us
Our history
Our vision and values
University partnerships
Team
Careers
Portfolio
Sustainability
Strategies
Our investment strategy
Our funds
Strategic assets
Property development finance
EIS & VCT
For shareholders
Share price
Board of directors
Financial reports & presentations
Regulatory news
Corporate governance
AIM Rule 26
Organisational structure
Annual Report
VCT
Northern Venture Trust
Northern 2 VCT
Northern 3 VCT
Insights & Research
Hub
test documents
PolyTherics receives milestone payment as Celtic Pharma progresses development of long-acting version of Blood Factor VIII produced using PolyTherics’ TheraPEG™ technology
View
Mercia Fund Management launches Mercia Growth Fund 2 – a new hybrid EIS/SEIS investment opportunity
View
PsiOxus Therapeutics completes patient enrolment for Phase II wasting disease therapeutic MT-102
View
Forward Group takes equity stake in Mercia Fund Management
View
DTRA awards US$3.3m contract to psioxus therapeutics to develop biodefence vaccine adjuvants
View
Mercia Fund Management announces over subscription to the SEIS portion of Mercia Growth Fund 1
View
Allinea MAPs Out New Performance Tool
View
National newspapers cover Mercia SEIS Fund
View
Mercia Fund Management highlights combined SEIS and EIS Funds at VCT and EIS Investor Forum
View
UK Government Awards 1.7M Grant To Psioxus Therapeutics For Second Phase I/II Clinical Trial Of Cancer Vaccine
View
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
Next
Loading...
Loading...
Disclaimer
Which of these options best describes you?
Please wait...
Disclaimers
Which of these options best describes you?
Please wait...
Loading...
Loading...
Disclaimer
Which of these options best describes you?
Please wait...
Disclaimers
Which of these options best describes you?
Please wait...